PharmaGraphX

Log in Get Started

Pegfilgrastim

Fulphila, Udenyca, Ziextenzo, Nyvepria, Fylnetra, Stimufend, Neulasta

Biologic agent

Standard

Half-life

15-80 hours

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Mechanism of action

PEGylated G-CSF with prolonged duration; neutrophil clearance-dependent kinetics

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Primary Mediastinal Large B-Cell Lymphoma
·Renal Pelvis and Ureter Urothelial Carcinoma
·AIDS-Related Lymphoma
·Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
·Ann Arbor Stage III Diffuse Large B-Cell Lymphoma

Interactions

No curated interaction pairs are recorded for Pegfilgrastim. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Bone pain
Injection site reactions

Pharmacokinetics

Half-life: 15-80 hours
Protein binding: N/A

Pregnancy & lactation

Not recorded for Pegfilgrastim. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement